PT2158217E - Anticorpo monoclonal humano neutralizante do receptor do factor de crescimento endotelial vascular e sua utilização - Google Patents

Anticorpo monoclonal humano neutralizante do receptor do factor de crescimento endotelial vascular e sua utilização Download PDF

Info

Publication number
PT2158217E
PT2158217E PT77684991T PT07768499T PT2158217E PT 2158217 E PT2158217 E PT 2158217E PT 77684991 T PT77684991 T PT 77684991T PT 07768499 T PT07768499 T PT 07768499T PT 2158217 E PT2158217 E PT 2158217E
Authority
PT
Portugal
Prior art keywords
monoclonal antibody
growth factor
vascular endothelial
factor receptor
human monoclonal
Prior art date
Application number
PT77684991T
Other languages
English (en)
Inventor
Kwi Hwa Kim
Young Woo Park
Jin San Yoo
Weon Sup Lee
Sang Ryeol Shim
Mi Hee Park
Jeong Eun Kang
Do Yun Kim
Joon Chul Lee
Dong Heon Lee
Too Hyon Cho
Sam Sook Sul
Young Guen Kwon
Bo Jeong Pyun
Chae Ok Yun
Nahm Ju Kim
Jae Won Jeon
Dong Sup Lee
Geun Bae Rha
Hyun Sook Jang
Hyeon Mi Yoo
Sung Woo Kim
Semi Kim
Sang Seok Koh
Original Assignee
Pharmabcine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmabcine Inc filed Critical Pharmabcine Inc
Publication of PT2158217E publication Critical patent/PT2158217E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PT77684991T 2007-06-13 2007-06-26 Anticorpo monoclonal humano neutralizante do receptor do factor de crescimento endotelial vascular e sua utilização PT2158217E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020070057719A KR100883430B1 (ko) 2007-06-13 2007-06-13 혈관내피성장인자 수용체를 중화하는 인간 단클론항체 및그 용도

Publications (1)

Publication Number Publication Date
PT2158217E true PT2158217E (pt) 2014-04-16

Family

ID=40129832

Family Applications (1)

Application Number Title Priority Date Filing Date
PT77684991T PT2158217E (pt) 2007-06-13 2007-06-26 Anticorpo monoclonal humano neutralizante do receptor do factor de crescimento endotelial vascular e sua utilização

Country Status (11)

Country Link
US (3) US9150650B2 (pt)
EP (1) EP2158217B1 (pt)
JP (1) JP5086430B2 (pt)
KR (1) KR100883430B1 (pt)
CN (1) CN101802003B (pt)
AU (1) AU2007354976B2 (pt)
CA (1) CA2691159C (pt)
DK (1) DK2158217T3 (pt)
ES (1) ES2450933T3 (pt)
PT (1) PT2158217E (pt)
WO (1) WO2008153237A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005222384A1 (en) * 2004-03-05 2005-09-22 Vegenics Limited Growth factor binding constructs materials and methods
KR101224468B1 (ko) * 2009-05-20 2013-01-23 주식회사 파멥신 신규한 형태의 이중표적항체 및 그 용도
US20130071397A1 (en) * 2009-12-29 2013-03-21 Yale University Inhibitors of vascular endothelial growth factor (vegf) receptors and methods of use thereof
US8883978B2 (en) 2010-05-11 2014-11-11 Institute For Cancer Research Antibodies to tumor endothelial marker 7R
WO2011145085A2 (en) * 2010-05-21 2011-11-24 Procognia (Israel) Ltd Novel antibodies and methods of use for the treatment and diagnosis of cancer
KR101217866B1 (ko) 2010-08-18 2013-01-03 한국원자력의학원 혈관신생 억제용 약학 조성물 및 혈관신생 억제용 활성물질을 스크리닝하는 방법
KR20120130658A (ko) * 2011-05-23 2012-12-03 주식회사 파멥신 펩타이드가 융합된 이중표적항체 및 그 용도
ES2894398T3 (es) 2011-06-03 2022-02-14 Xoma Technology Ltd Anticuerpos específicos para TGF-beta
CA2854153A1 (en) 2011-11-02 2013-05-10 Apexigen, Inc. Anti-kdr antibodies and methods of use
CN103087192B (zh) * 2011-11-02 2015-02-04 埃派斯进有限公司 抗-kdr抗体和使用方法
CA2892193C (en) 2012-11-21 2018-06-19 Pharmabcine Inc. Dual-target antibody targeting vegfr-2 and dll4, and pharmaceutical composition including the same
KR101615619B1 (ko) 2014-08-07 2016-04-26 주식회사 파멥신 c-Met 특이적 인간 항체 및 그 제조방법
JP6616833B2 (ja) 2014-11-25 2019-12-04 ファームアブシン インコーポレイテッド 新規ＥＧＦＲｖＩＩＩ抗体及びこれを含む組成物
CN107531789B (zh) * 2015-04-14 2021-08-10 中央研究院 用于抗血管新生和标靶癌症治疗的抗vegfr2人类抗体
BR112020007755A2 (pt) 2017-10-20 2020-10-20 Pharmabcine Inc. anticorpo anti-vista e uso do mesmo
KR102311838B1 (ko) 2017-12-27 2021-10-14 주식회사 파멥신 항-pd-l1 항체 및 이의 용도
KR102644938B1 (ko) * 2018-03-19 2024-03-07 주식회사 파멥신 항-vegfr-2 항체
CA3136975A1 (en) 2019-08-14 2021-02-18 Pharmabcine Inc. Anti-tie2 antibody and use thereof
JP2024512260A (ja) * 2021-02-19 2024-03-19 ドットバイオ プライベート リミテッド Ｖｅｇｆａ結合分子
KR20230039943A (ko) 2021-09-15 2023-03-22 주식회사 파멥신 항-vegfr2(kdr) 개량 항체 및 이의 용도

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL89489A0 (en) 1988-03-09 1989-09-10 Hybritech Inc Chimeric antibodies directed against human carcinoembryonic antigen
WO1989009622A1 (en) 1988-04-15 1989-10-19 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
WO1989009825A1 (en) 1988-04-16 1989-10-19 Celltech Limited Method for producing recombinant dna proteins
AU4128089A (en) * 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
DE4103975A1 (de) 1991-02-09 1992-08-13 Thomson Brandt Gmbh Verfahren zur verkuerzung der zugriffszeit
US5367057A (en) * 1991-04-02 1994-11-22 The Trustees Of Princeton University Tyrosine kinase receptor flk-2 and fragments thereof
US5270458A (en) * 1991-04-02 1993-12-14 The Trustees Of Princeton University Nucleic acids encoding fragments of hematopoietic stem cell receptor flk-2
US5185438A (en) * 1991-04-02 1993-02-09 The Trustees Of Princeton University Nucleic acids encoding hencatoporetic stem cell receptor flk-2
US5861301A (en) * 1992-02-20 1999-01-19 American Cayanamid Company Recombinant kinase insert domain containing receptor and gene encoding same
AU4025193A (en) 1992-04-08 1993-11-18 Cetus Oncology Corporation Humanized C-erbB-2 specific antibodies
DE69233803D1 (de) 1992-10-28 2011-03-31 Genentech Inc Verwendung von vaskulären Endothelwachstumsfaktor-Antagonisten
US5712395A (en) * 1992-11-13 1998-01-27 Yissum Research Development Corp. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5981569A (en) * 1992-11-13 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
US6177401B1 (en) * 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5861499A (en) * 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
US5840301A (en) 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
US6448077B1 (en) * 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
AUPM379394A0 (en) 1994-02-10 1994-03-03 Ludwig Institute For Cancer Research Immunointeractive molecules - i
US6811779B2 (en) * 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
WO1998022616A1 (fr) 1996-11-21 1998-05-28 Kyowa Hakko Kogyo Co., Ltd. Anticorps monoclonal avec recepteur f1t-1 vegf anti-humain
CN1095683C (zh) * 1997-01-08 2002-12-11 郑方胜 经食管心室起搏导电球囊电极导管
EP1086705A4 (en) 1998-05-20 2002-02-06 Kyowa Hakko Kogyo Kk INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) ACTIVITY
KR20000034847A (ko) 1998-11-17 2000-06-26 성재갑 인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물
JP4926320B2 (ja) * 1999-04-28 2012-05-09 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム Ｖｅｇｆの選択的阻害による癌処置のための組成物および方法
AU2001243418A1 (en) 2000-03-03 2001-09-17 Imclone Systems Incorporated Ve-cadherin and vegfr-2 antagonists for therapeutic modulation of angiogenesis
CA2409991A1 (en) * 2000-05-24 2001-11-29 Imclone Systems Incorporated Bispecific immunoglobulin-like antigen binding proteins and method of production
PT1916001E (pt) * 2002-03-04 2011-07-18 Imclone Llc Anticorpos humanos específicos para kdr e suas utilizações
CN1187373C (zh) * 2002-03-20 2005-02-02 上海中信国健药业有限公司 人源化抗血管内皮生长因子单克隆抗体及其制法和药物组合物
KR100793095B1 (ko) 2003-10-01 2008-01-10 주식회사 프로메디텍 Ｂａｃｅ 저해효능을 가진 신규한 술폰 아미드 유도체

Also Published As

Publication number Publication date
EP2158217A4 (en) 2011-06-29
CA2691159A1 (en) 2008-12-18
AU2007354976A1 (en) 2008-12-18
EP2158217B1 (en) 2014-01-15
US9249219B2 (en) 2016-02-02
CA2691159C (en) 2014-07-29
US20110065176A1 (en) 2011-03-17
CN101802003A (zh) 2010-08-11
US20140288274A1 (en) 2014-09-25
EP2158217A1 (en) 2010-03-03
WO2008153237A1 (en) 2008-12-18
AU2007354976B2 (en) 2014-03-13
US20140275488A1 (en) 2014-09-18
US9249220B2 (en) 2016-02-02
DK2158217T3 (da) 2014-04-07
JP5086430B2 (ja) 2012-11-28
KR20080109417A (ko) 2008-12-17
ES2450933T3 (es) 2014-03-25
CN101802003B (zh) 2013-02-13
KR100883430B1 (ko) 2009-02-12
US9150650B2 (en) 2015-10-06
JP2010529853A (ja) 2010-09-02

Similar Documents

Publication Publication Date Title
EP2158217A4 (en) THE VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR NEUTRALIZING HUMAN MONOCLONAL ANTIBODY AND APPLICATION THEREOF
HRP20181616T1 (hr) Potpuno ljudska anti-vap-1 monoklonska antitijela
EP2046384A4 (en) ANTIBODIES BLOCKING FIBROBLAST GROWTH FACTOR RECEPTOR ACTIVATION AND METHODS OF USING THE SAME
IL200610A0 (en) Human monoclonal anti-ip-10 antibodies and uses thereof
CY2016016I2 (el) Ανθρωπινο αντισωμα αντι-υποδοχεα επιδερμικου αυξητικου παραγοντα
IL193675A0 (en) Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
IL216381A0 (en) Antagonistic human light-specific human monoclonal antibodies
IL179672A (en) Monoclonal antibodies against 3 cd human
SG10201608268RA (en) Human antibodies that bind cxcr4 and uses thereof
IL200615A0 (en) Monoclonal human tumor-specific antibody
EP2185718A4 (en) HUMAN MONOCLONAL ANTIBODIES AND METHOD FOR THEIR MANUFACTURE
EP2409992A4 (en) MONOCLONAL ANTI-FACTOR OF TUMOR NECROSIS ALPHA HUMAN AND USE THEREOF
EP2123677A4 (en) ANTI-BRAK HUMAN MONOCLONAL ANTIBODY (CXCL14) AND USE THEREOF
ZA200901165B (en) Antagonistic human light-specific human monoclonal antibodies
ZA200807764B (en) Tumor therapy with an antibody for vascular endothelial groth factor and an antibody for human epithelial growth receptor type 2